Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|December 15, 2022
Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL studyJosé Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Domínguez, et al.Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|May 4, 2021
Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocolJosé Seijas-Amigo, Diego Rodríguez-Penas, Ana Estany-Gestal, et al.The American Journal of Cardiology|August 26, 2023
Clinical Benefit of Bempedoic Acid in Randomized Clinical TrialsAlberto Cordero, Rosa Fernandez Olmo, Carlos García Santos-Gallego, et al.Atherosclerosis|October 8, 2020
Estimation of the major cardiovascular events prevention with InclisiranAlberto Cordero, Carlos G Santos-Gallego, Lorenzo Fácila, et al.Journal of Diabetes and Metabolic Disorders|February 1, 2021
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trialsAlberto Cordero, Moisés Rodríguez-Mañero, Lorenzo Fácila, et al.Revista Espanola De Cardiologia (English Ed.)|December 25, 2016
Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart FailureInés Gómez-Otero, Andreu Ferrero-Gregori, Alfonso Varela Román, et al.Journal of Cardiovascular Pharmacology|October 11, 2022
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness AnalysisJosé Seijas-Amigo, Alberto Cordero, Rosa F Olmo, et al.European Journal of Clinical Investigation|August 30, 2022
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registryAlberto Cordero, Mª Rosa Fernández Olmo, Gustavo A Cortez Quiroga, et al.Primary Care Diabetes|May 25, 2023
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phaseJosé Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, et al.Journal of Cardiovascular Pharmacology|January 5, 2022
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL RegistryAlberto Cordero, M Rosa Fernández Del Olmo, Gustavo A Cortez Quiroga, et al.Pageof 2